Juno, Kite Stand By Their Products As Novartis's Shift Renews CAR-T Concerns
Novartis's consolidation of its cell and gene therapy division into its corporate R&D operation has other leading CAR-T developers defending their therapeutic candidates against technical and manufacturing doubts.
You may also be interested in...
Cell and gene therapies, described as the most exciting developments in the life sciences industry, pick up more momentum with every passing month. The spiraling enthusiasm for an activity that will change how health care is delivered was captured by GE, GSK and other key industry players at a leading UK life sciences industry meeting in spring 2017.
With all eyes on the race to get the autologous cell immunotherapies to market, Kite announces it could soon see late-stage data on its lead candidate.
The FDA lifted a clinical hold on the Phase II ROCKET clinical trial for Juno's lead CAR-T therapy candidate JCAR015 less than a week after it was instituted, allowing the company to proceed without using fludarabine in a pre-conditioning chemotherapy regimen.